ECRONICON OPEN ACCESS

EC GASTROENTEROLOGY AND DIGESTIVE SYSTEM

Review Article

Finding and Updates in Celiac Disease

Taufner G H[1] and Afrânio Côgo Destefani[2]*

[1]Biomedic, Master student in Biotechnology from the Federal University of Espírito Santo (UFES), Av. Marechal Campos, 1468 – Maruípe, Vitória, ES – Brazil

[2]Pharmacist Biochemist, PhD Student in Biotechnology from the Federal University of Espírito Santo (UFES), Av. Marechal Campos, 1468 – Maruipe, Vitória, ES – Brazil

***Corresponding Author:** Afrânio Côgo Destefani, Pharmacist Biochemist, PhD Student in Biotechnology from the Federal University of Espírito Santo (UFES), Av. Marechal Campos, 1468 – Maruípe, Vitória, ES – Brazil.

Received: December 28, 2016; **Published:** January 16, 2017

Abstract

Celiac disease is an immune system issue initiated by gluten in hereditarily powerless people. It can bring about intraintestinal and extraintestinal appearances of disease including looseness of the bowels, weight reduction, iron deficiency, osteoporosis, or lymphoma. Analysis of celiac disease is made through starting serologic testing and afterward affirmed by histopathologic examination of duodenal biopsies. For the most part celiac disease is a considerate issue with a decent forecast in the individuals who hold fast to a without gluten consume less calories. In any case, in hard-headed disease, inconveniences may build up that warrant extra testing with more progressed radiologic and endoscopic techniques. This article surveys the ebb and flow procedure to analyze celiac disease and the more up to date modalities to evaluate for related entanglements.

Keywords: *Gluten; Villous Decay; Celiac Disease; Enteropathy; Celiac Sprue*

Introduction

Celiac disease (CD) is an immune system issue initiated by gluten in hereditarily vulnerable people described by intraepithelial lymphocytosis, grave hyperplasia, and villous decay of the little entrail. It is a perpetual provocative express that mends on rejection of gluten-containing sustenances from the eating routine. The predominance of CD is around 1% of the overall public worldwide [1]. Gluten from wheat, grain, and rye are advanced in glutamines and prolines, which experience halfway processing in the little inside bringing about peptide subordinates that are deamidated by tissue transglutaminase, which renders them immunogenic to those with CD [2]. Active CD can bring about intestinal and extraintestinal indications of disease including looseness of the bowels, weight reduction, iron deficiency, osteoporosis, joint pain, hepatitis, or harm. A few patients are additionally asymptomatic [3].

Finding of CD is by and large started through serologic testing with anti-tissue transglutaminase IgA antibodies (against tTG), gliadin-determined peptide antibodies IgA/IgG (hostile to DGP), endomysial IgA antibodies (EMA), or potentially antigliadin antibodies (AGA). Given the lower affectability and specificity of AGA tests for CD, the EMA, hostile to tTG, and against DGP have to a great extent supplanted other serologic testing [4]. Following positive serologic testing, conclusion ought to by and large be affirmed by histopathologic examination of duodenal biopsies.

For the most part CD is a benevolent issue with a decent forecast in those patients that can hold fast to a without gluten eat less carbs. Be that as it may, in those with headstrong disease, entanglements may create, which warrant extra testing with more progressed

radiologic and endoscopic strategies including magnetic resonance enterography/enteroclysis (MRE), PET/computed tomography (CT), capsule endoscopy, and device-assisted enteroscopy [5].

Pathogenesis

CD creates in hereditarily vulnerable people who are presented to gluten. The clinical presentation of CD can shift incredibly including the time of onset, exhibiting indications, the level of counter acting agent titers, and a scope of histopathologic discoveries, which can likely be clarified by the connection between hereditary inclination and ecological introduction.

Hereditary Inclination

Kin examines in CD have exhibited an ailment concordance of around 80% in monozygotic twins and under 20% in dizygotic twins demonstrating a hereditary connection. The major hereditary determinants in CD include the HLA, which is assessed to add to around 36% of the hereditability between siblings [6-9].

HLA-DQ particles are comprised of two subunits, α and β, which are encoded by two distinct qualities of the class II MHC atom: HLA-DQA1 and HLA-DQB1, individually. In CD, it has been found that 90% of patients convey the alleles DQA1*05 and DQB1*02, which make up the HLA-DQ2 heterodimer. All the more particularly, they have a tendency to have the HLA-DQ2.5 variation, which includes the DQA1*05:01 and DQB1*02:01 qualities in cis design on the DR3 haplotype [10]. This atom has a high fondness for the peptides that are framed from deficient absorption of gluten, which brings about their presentation and resultant intestinal aggravation. HLA impact on CD powerlessness likewise shows a measurement impact. Homozygous HLA-DQ2 people, for instance, may have an expanded hazard for CD and enteropathy-related T-cell lymphoma (EATL) [11-13].

Of the 10% who have not acquired the HLA-DQ2.5 particle (DQA1*05:01 and DQB1*02:01 alleles), most have acquired the DQA1*03 and DQB1*03:02 alleles of the HLA-DQ8 atom [6]. Furthermore, there are additionally non-HLA hereditary components that assume a part in the advancement of malady. In Western nations around 40% of the all inclusive community have either of the HLA-DQ2/HLA-DQ8 heterodimers, yet just 1% of people create CD [6]. This demonstrates there must be other hereditary and natural components that add to the improvement of illness. Through far reaching affiliation contemplates, a few diverse non-HLA alleles connected with danger of CD have been discovered [14]. Currently there are around 40 loci outside of HLA that have been resolved through all inclusive affiliation concentrates that have been found to either ensure or incline to CD, in spite of the fact that they contribute little when contrasted and HLA [10].

Natural Exposure and Trigger Factors

Not withstanding hereditary inclination, patients with CD should be presented to gluten to build up the illness. Gluten is the capacity protein for the oat grains of wheat, rye, and grain. There has been some felt that the planning of gluten presentation, the measure of gluten introduction, and breastfeeding examples may impact the improvement of CD. A lot of gluten presentation without breastfeeding may build the danger of future CD, despite the fact that information are conflicting [15-18]. There has additionally been some work hoping to assess if different elements, for example, gastrointestinal contamination, surgery, or certain medications, might be the trigger for advancement of CD [17,19,20].

Immunology

Gluten proteins are not entirely processed by the gastric, pancreatic, and intestinal brush fringe proteases. The rest of the peptides go through the epithelial boundary of the little entrail and enter the lamina propria through transcellular and paracellular systems. This triggers the intrinsic and versatile safe reaction in patients with CD prompting to intestinal inflammation [15].

Gluten peptides were at first thought to initiate a natural invulnerable reaction. Be that as it may, nongluten, proteins, for example, the wheat amylase-trypsin inhibitor, have been exhibited to actuate macrophages, monocytes, and dendritic cells by means of toll-like receptor 4, which is the receptor for bacterial lipopolysaccharide [21]. The inborn reaction is showed by expanded articulation of interleukin-15 by enterocytes, which prompts to initiation of intraepithelial lymphocytes (IEL) that express the characteristic executioner T-cell receptors [22].

The versatile reaction happens inside the lamina propria, where gluten-responsive CD4+ T cells perceive gluten peptides exhibited on HLA-DQ2.5/HLA-DQ8 particles. This happens in light of the fact that tissue transglutaminase is discharged by fiery and endothelial cells because of mechanical aggravation and irritation. It cross-joins with gluten proteins and deamidates gliadin, in this manner adjusting the charge and adaptation of gliadin peptides. These progressions enormously increment the coupling proclivity of gliadin to HLA-DQ2 or HLA-DQ8 atoms, prompting to T-cell incitement. This enacts the antigen exhibiting cells prompting to auto counter acting agent arrangement (tTG), proinflammatory cytokines including interferon-γ, and ensuing tissue damage, prompting to grave hyperplasia and villous blunting [15,23-28].

Clinical components

The clinical components of CD range from traditional side effects, to non-classical and symptomatic, to asymptomatic. Traditional side effects by and large incorporate those subsequent from malabsorption including the runs, steatorrhea, weight reduction, and development confinement in kids. Non-classical and symptomatic patients have a tendency to have either some gastrointestinal side effects, for example, stomach torment or stoppage, or may have extraintestinal side effects. Time of onset of illness is at any age when there is introduction to gluten, and the presentation can fluctuate contingent upon period of presentation. Youngsters who give CD mid tend to give more extreme illness showed as development issues and repetitive stomach torment, and less normally (around 10%) with diarrhea [15]. Older adolescents and grown-ups, in any case, regularly have unobtrusive indications that might be misdiagnosed as crabby gut syndrome [3].

Gastrointestinal Manifestations

The exemplary gastrointestinal appearances of CD result from villous decay in the small digestive tract prompting to malabsorption. This prompts to the improvement of loose bowels, steatorrhea, weight reduction, and development disappointment in kids. Malabsorption additionally brings about a large number of the regular confusions optional to supplement misfortune including iron-insufficiency weakness, neurologic scatters from vitamin B lacks, and osteopenia from vitamin D inadequacy.

As serologic testing has enhanced, more grown-ups are being determined to have less serious manifestations. Numerous grown-ups create bad tempered inside syndrome–type side effects including minor gastrointestinal dissensions, for example, stomach torment, sailing, stoppage, or mellow looseness of the bowels. Frequently, be that as it may, these people are analyzed on account of healthful insufficiencies bringing about iron-lack frailty, osteoporosis, or extraintestinal appearances as sketched out next.

CD has additionally been connected to other gastrointestinal issue that range from a mellow increment in transaminases to liver disappointment, liver growth, and pancreatic cancer [15,21,29,30].

Extraintestinal Manifestations

Not withstanding expected appearances as a consequence of villous decay, there have been numerous different issue connected to CD. These incorporate iron-inadequacy sickliness, neuropsychiatric infection, lymphoma, joint pain, and metabolic bone disease [10,31-41].

Press lack pallor is regularly reported in patients with CD even in those without malaborptive or gastrointestinal side effects. In asymptomatic patients with iron-insufficiency pallor, the commonness of CD was found to run from 2.3% to 5.0%, though in those people with gastrointestinal manifestations and iron-inadequacy sickliness the pervasiveness extended from 10.3% to 15% [22,42].

Neurologic or psychiatric maladies have been depicted in patients with CD including cerebral pain, fringe neuropathies, ataxia, dysthymia, misery, tension, and epilepsy [34-36].

CD has likewise been connected with the improvement of lymphoma. Albeit traditionally connected with the advancement of EATL, patients are at a more serious danger of creating different sorts of lymphoma including intestinal and extraintestinal non-Hodgkin lymphoma. Contemplates have shown that the institutionalized frequency proportion of non-Hodgkin lymphoma in patients with CD contrasted and the all inclusive community runs somewhere around 2.7% and 6.3% [22].

CD has likewise been connected to a few distinctive immune system issue including sort 1 diabetes mellitus and immune system thyroid malady. One review found that immune system maladies happened in 14% of patients with CD contrasted and just 2.8% of control subjects. The hazard additionally was found to increment with term of gluten exposure [43]. One contention for screening patients for CD is that it might likewise decrease the danger of improvement of different issue, in spite of the fact that the information on this are limited [15,44].

Conventional way to deal with testing

In light of the scope of patient presentations from asymptomatic to malaborptive indications, and the related intestinal and extraintestinal signs that may create, it is important to know when and which patients to test for CD. The American College of Gastroenterology Clinical Guideline distributed in the American Journal of Gastroenterology in 2013, laid out those people who ought to be tried for CD (Box 1)[2].

Box 1.
Proposals for screening in celiac infection

1. Patients with manifestations, signs, or research facility prove suggestive of malabsorption, for example, interminable loose bowels with weight reduction, steatorrhea, postprandial stomach torment, and bloating, ought to be tried for CD—solid proposal, abnormal state of confirmation.

2. Patients with side effects, signs, or research center proof for which CD is a treatable cause ought to be considered for testing for CD—solid proposal, direct level of confirmation.

3. Patients with a first-degree relative who has an affirmed finding of CD ought to be tried in the event that they give conceivable hints or indications or research center confirmation of CD—solid suggestion, abnormal state of proof.

4. Consider testing of asymptomatic relatives with a first-degree relative who has an affirmed finding of CD—contingent suggestion, abnormal state of confirmation.

5. Celiac infection ought to be looked for among the clarifications for raised serum aminotransferase levels when no other cause is found—solid suggestion, abnormal state of confirmation.

6. Patients with sort I diabetes mellitus ought to be tried for CD if there are any stomach related manifestations, or signs, or research facility confirm suggestive of celiac sickness—solid proposal, abnormal state of proof.

As illustrated in Box 1, testing ought to be performed on those with signs or side effects of malabsorption including the runs, weight reduction, or vitamin inadequacies. Given the hereditary hereditability, all kids and any symptomatic patients with first-degree relatives with CD ought to be tried, and a contention can be made for additionally testing subclinical grown-ups. CD ought to likewise be tried in patients with lifted serum aminotransferase levels without other cause, or in patients with immune system ailments, for example, sort 1 diabetes mellitus with side effects or predictable research facility discoveries.

Serologic Testing

Serologic testing for analysis ought to be performed on patients while on a gluten-containing diet. Noninvasive screening for CD incorporates serologic testing with EMA, AGA, antitissue against tTG, and hostile to DGP. Given the lower affectability and specificity of AGA for CD, the EMA, against tTG, and hostile to DGP tests have to a great extent supplanted AGA testing [4].

Taking after AGA, IgA antibodies against the endomysium (EMA) of monkey throat was found as being exceedingly touchy and particular in the conclusion of CD [45]. IgA EMA has been assessed by many reviews and the pooled affectability was observed to be 97.4% with a specificity of 96.1%. Nonetheless, there was some variety in affectability in the reviews with one reporting the affectability as 75%. The IgA EMA can likewise be performed utilizing human umbilical rope as substrate with pooled affectability and specificity of 90.2% and 99.6%, respectively [22].

Additionally inquire about recognized the compound tissue transglutaminase as the autoantigen that responds with EMA, which prompted to the improvement of protein connected immunosorbent examines that distinguish hostile to tTG [46]. Most business tests for IgA tTG utilize human-recombinant or red-cell inferred tTG as a substrate with blended age populace pooled evaluations of affectability and specificity of 90.2% and 95.4%, separately.

Most EMA and hostile to tTG testing are IgA-based tests, and in this way an aggregate IgA ought to be measured to prohibit IgA lack. Particular IgA inadequacy has a predominance of around 1.7% to 3% [22,47] in patients with CD, which is 10 to 15 times more basic than in the all inclusive community.

All the more as of late, hostile to DGP have likewise been considered, which are IgG-or IgA-based and can hence be utilized for testing as a part of patients with IgA-insufficiency. DGP IgA and DGP IgG antibodies have been appeared to have an affectability of 94% and specificity of 99%, and an affectability of 92% and 100%, respectively [15,48].

There is proceeded with civil argument to figure out whether noninvasive testing could be utilized as the main testing required for analysis of CD. In youngsters the utilization of two separate serologic tests if constructive more prominent than 10 times the maximum furthest reaches of ordinary with constructive hereditary markers for HLA-DQ2 and HLA-DQ8 has been proposed as a conceivable testing calculation, accordingly maintaining a strategic distance from the requirement for upper endoscopy with biopsy [49]. However, 2% to 3% of individuals with CD have negative outcomes in serologic tests, have low serologic titers, or have fluctuating titers; therefore, upper endoscopy with biopsy is still the highest quality level for affirmation.

Hereditary Testing

HLA genotyping in the conclusion of CD, particularly to search for HLA-DQ2.5 and HLA-DQ8, is helpful for its negative prescient esteem. Under 1% of patients with CD are negative for HLA-DQ2 and HLA-DQ8 [10]. The positive prescient esteem, be that as it may, is low in light of the fact that a substantial extent of people without CD convey either HLA-DQ2.5 or HLA-D8. In particular, the pervasiveness of DQ2 in the overall public is around 30% to 40%, and the commonness of DQ8 in the all inclusive community is around 5% to 10% [10,50].

HLA genotyping has along these lines been observed to be useful in patients with suspected CD who neglect to react to a sans gluten eating routine, to preclude the ailment. HLA writing can likewise be valuable in patients who have self-determined themselves to have CD and are on a sans gluten abstain from food at the season of presentation, in light of the fact that serologic testing and biopsy might be less precise. HLA writing can likewise preclude CD in high-hazard patients, for example, patients with first-degree relatives with CD, in this way minimizing further testing [10].

Summary

In the underlying analysis of CD, there are different helpful modalities incorporating serologic testing with high affectability and specificity, which can then be affirmed through duodenal biopsy exhibiting trademark components of expanded IEL, sepulcher hyperplasia, and villous decay. Notwithstanding, in convoluted CD, additionally imaging and progressed endoscopic methods have been examined and are valuable in diagnosing related difficulties including RCD, malignancies, for example, little gut lymphoma, and EATL, and diagnosing further confusions, for example, ulcerative jejunoileitis.

Bibliography

1. Ludvigsson JF., *et al*. "The Oslo definitions for coeliac disease and related terms". *Gut* 62.1 (2013): 43-52.

2. Rubio-Tapia A., *et al*. "ACG Clinical Guidelines: Diagnosis and Management of Celiac Disease". *American Journal of Gastroenterology* 108.5 (2013): 656-676.

3. Kelly CP., *et al*. "Advances in diagnosis and management of celiac disease". *Gastroenterology* 148.6 (2015): 1175-1186.

4. Prince HE. "Evaluation of the INOVA Diagnostics Enzyme-Linked Immunosorbent Assay Kits for Measuring Serum Immunoglobulin G (IgG) and IgA to Deamidated Gliadin Peptides". *Clinical and Vaccine Immunology* 13.1 (2006): 150-151.

5. Branchi F., *et al*. "Enteroscopy and radiology for the management of celiac disease complications: Time for a pragmatic roadmap". *Digestive and Liver Disease*48.6 (2016): 578-586.

6. Medrano LM., *et al*. "HLA and celiac disease susceptibility: new genetic factors bring open questions about the HLA influence and gene-dosage effects". *PLoS One Public Library of Science*7.10 (2012): e48403.

7. Risch N. "Assessing the role of HLA-linked and unlinked determinants of disease". *American Journal of Human Genetics*40.1 (1987): 1-14.

8. Petronzelli F.,*et al*. "Genetic contribution of the HLA region to the familial clustering of coeliac disease". *Annals of Human Genetics* 61.Pt 4 (1997): 307-317.

9. Bevan S., *et al*. "Contribution of the MHC region to the familial risk of coeliac disease". *Journal of Medical Genetics* 36.9 (1999): 687-690.

10. Ludvigsson JF., *et al*. "Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology". *Gut. BMJ Publishing Group Ltd and British Society of Gastroenterology*63.8 (2014): 1210-1228.

11. Al-Toma A., *et al*. "Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma". *Clinical Gastroenterology and Hepatology*4.3 (2006): 315-319.

12. Pietzak MM., *et al*. "Stratifying risk for celiac disease in a large at-risk United States population by using HLA alleles". *Clinical Gastroenterology and Hepatology*7.9 (2009): 966-971.

13. Liu E., *et al*. "Risk of pediatric celiac disease according to HLA haplotype and country". *New England Journal of Medicine*371 (2014): 42-49.

14. Dieli-Crimi R., *et al*. "The genetics of celiac disease: A comprehensive review of clinical implications". *Journal of Autoimmunity*64 (2015): 26-41.

15. Lebwohl B., *et al*. "Celiac disease and non-celiac gluten sensitivity". *BMJ*351 (2015): h4347.

16. Roberts SE., *et al*. "Perinatal risk factors and coeliac disease in children and young adults: a record linkage study". *Alimentary Pharmacology & Therapeutics*29.2 (2009): 222-231.

17. Welander A., *et al*. "Infectious Disease and Risk of Later Celiac Disease in Childhood". *Pediatrics*125.3 (2010): e530-e536.

18. Aronsson CA., *et al*. "Age at gluten introduction and risk of celiac disease". Pediatrics 135.2 (2015): 239-245.

19. Stene LC., *et al*. "Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study". *American Journal of Gastroenterology* 101.10 (2006): 2333-2340.

20. Riddle MS., *et al*. "The incidence and risk of celiac disease in a healthy US adult population". *AmericanJournal of Gastroenterology* 107.8 (2012): 1248-1255.

21. Volta U., *et al*. "Coeliac disease hidden by cryptogenic hypertransaminasaemia". *Lancet* 352 (1998): 26-29.

22. Rostom A., *et al*. "American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease". *Gastroenterology*131.6 (2006): 1981-2002.

23. Sollid LM. "Coeliac disease: dissecting a complex inflammatory disorder". *Nature Reviews Immunology*2.9 (2002): 647-655.

24. Nilsen EM., *et al*. "Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease". *Gastroenterology*115.3 (1998): 551-563.

25. Mohamed BM., *et al*. "Increased protein expression of matrix metalloproteinases -1, -3, and -9 and TIMP-1 in patients with gluten-sensitive enteropathy". *Digestive Diseases and Sciences*51 (2006): 1862-1868.

26. Soto C., *et al*. "Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy". *Nature Medicine*4.7 (1998): 822-826.

27. Schuppan D., *et al*. "Exposing gliadin as a tasty food for lymphocytes". *Nature Medicine*4.6 (1998): 666-667.

28. van de Wal Y., *et al*. "Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity". *Journal of Immunology*161.4 (1998): 1585-15888.

29. Kaukinen K., *et al*. "Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure". *Gastroenterology*122.4 (2002): 881-888.

30. Elfström P., *et al*. "Low risk of gastrointestinal cancer among patients with celiac disease, inflammation, or latent celiac disease". *Clinical Gastroenterology and Hepatology*10.1 (2012): 30-36.

31. Bergamaschi G., *et al*. "Anemia of chronic disease and defective erythropoietin production in patients with celiac disease". *Haematologica* 93.12 (2008): 1785-1791.

32. Sanders DS., *et al*. "Association of adult coeliac disease with irritable bowel syndrome: A case-control study in patients fulfilling ROME II criteria referred to secondary care". *Lancet* 358.9292 (2001): 1504-1508.

33. Hadjivassiliou M., *et al*. "Does cryptic gluten sensitivity play a part in neurological illness?" *Lancet (London, England)* 347.8998 (1996): 369-371.

34. Ludvigsson JF., *et al*. "A population-based study of coeliac disease, neurodegenerative and neuroinflammatory diseases". *Alimentary Pharmacology and Therapeutics* 25.11 (2007): 1317-1327.

35. Hadjivassiliou M., *et al*. "Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics". *Brain* 126.3 (2003): 685-691.

36. Ludvigsson JF., *et al*. "Coeliac disease and risk of mood disorders--a general population-based cohort study". *Journal of Affective Disorders* 99.1-3 (2007): 117-126.

37. Groll A., *et al*. "Short stature as the primary manifestation of coeliac disease". *Lancet (London, England)* 2.8204 (1980): 1097-1099.

38. Olmos M., *et al*. "Systematic review and meta-analysis of observational studies on the prevalence of fractures in coeliac disease". *Digestive and Liver Disease* 40.1 (2008): 46-53.

39. Ludvigsson JF., *et al*. "Celiac disease and risk of liver disease: a general population-based study". *Clinical Gastroenterology and Hepatology* 5.1 (2007): 63-69.e1.

40. Ludvigsson JF., *et al*. "Celiac disease and risk of adverse fetal outcome: a population-based cohort study". *Gastroenterology* 129.2 (2005): 454-463.

41. West J., *et al*. "Malignancy and mortality in people with coeliac disease: population based cohort study". *British Medical Journal* 329.7468 (2004): 716-719.

42. Dickey W., *et al*. "Gastric as well as duodenal biopsies may be useful in the investigation of iron deficiency anaemia". *Scandinavian Journal of Gastroenterology* 32.5 (1997): 469-472.

43. Ventura A., *et al*. "Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disorders in Celiac Disease". *Gastroenterology* 117.2 (1999): 297-303.

44. Aggarwal S., *et al*. "Screening for celiac disease in average-risk and high-risk populations". *Therapeutic Advances in Gastroenterology* 5.1 (2012): 37-47.

45. Leffler DA and Schuppan D. "Update on serologic testing in celiac disease". *American Journal of Gastroenterology* 105.12 (2010): 2520-2524.

46. Dieterich W., *et al*. "Identification of tissue transglutaminase as the autoantigen of celiac disease". *Nature Medicine* 3.7 (1997): 797-801.

47. Cataldo F., *et al*. "Celiac disease and selective immunoglobulin A deficiency". *Journal of Pediatrics* 131.2 (1997): 306-308.

48. Sugai E., *et al*. "Accuracy of testing for antibodies to synthetic gliadin-related peptides in celiac disease". *Clinical Gastroenterology and Hepatology* 4.9 (2006): 1112-1117.

49. Husby S., *et al*. "European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease". *Journal of Pediatric Gastroenterology and Nutrition* 54.1 (2012): 136-160.

50. Abadie V., *et al*. "Integration of genetic and immunological insights into a model of celiac disease pathogenesis". *Annual Review of Immunology* 29 (2011): 493-525.

Volume 1 Issue 6 January 2017